Boundary Capital Partners joins syndicate and Illumina to invest in Desktop Genetics’ technology to support the platform’s integration with NGS pipelines and improve CRISPR genome editing workflows. Desktop Genetics Ltd (“DTG” or “the Company”), a software company revolutionizing the way biologists use CRISPR gene editing technology, announced today that it has received investment funding from…

Boundary Capital Partners LLP is authorised and regulated by the Financial Conduct Authority.
Boundary Capital Partners LLP Reg: OC387581 VAT: 204012873
Registered office: 35 Kingsland Road, London, England, E2 8AA

STAY CONNECTED WITH US: